 ROCKVILLE, Md., Nov. 08, 2022 GLOBE NEWSWIRE -- Supernus Pharmaceuticals, Inc. Nasdaq: SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system CNS diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will present a Company overview and update, as well as host investor meetings, at the following November conferences: 